User login
A 43-year-old woman who was BRCA1 and -2 negative presented initially in 2002, when she was 35 years old, with inflammatory breast carcinoma on the right side. She was 9 months post partum. A biopsy revealed that the tumor was estrogen-receptor (ER)/progesterone- receptor (PR) negative and HER2 (human epidermal growth factor receptor–2) positive. She received neoadjuvant chemotherapy with adriamycin plus docetaxel for 6 cycles, followed by right mastectomy and prophylactic left mastectomy. There was no residual disease in the breast. After mastectomy, the patient underwent CMF (cyclophosphamide, methotrexate, and fluorouracil) chemotherapy for 3 months, as well as radiation therapy to the chest wall. Adjuvant trastuzumab was started concurrently with the CMF chemotherapy, and was continued for 1 year.
*For a PDF of the full article, click on the link to the left of this introduction.
A 43-year-old woman who was BRCA1 and -2 negative presented initially in 2002, when she was 35 years old, with inflammatory breast carcinoma on the right side. She was 9 months post partum. A biopsy revealed that the tumor was estrogen-receptor (ER)/progesterone- receptor (PR) negative and HER2 (human epidermal growth factor receptor–2) positive. She received neoadjuvant chemotherapy with adriamycin plus docetaxel for 6 cycles, followed by right mastectomy and prophylactic left mastectomy. There was no residual disease in the breast. After mastectomy, the patient underwent CMF (cyclophosphamide, methotrexate, and fluorouracil) chemotherapy for 3 months, as well as radiation therapy to the chest wall. Adjuvant trastuzumab was started concurrently with the CMF chemotherapy, and was continued for 1 year.
*For a PDF of the full article, click on the link to the left of this introduction.
A 43-year-old woman who was BRCA1 and -2 negative presented initially in 2002, when she was 35 years old, with inflammatory breast carcinoma on the right side. She was 9 months post partum. A biopsy revealed that the tumor was estrogen-receptor (ER)/progesterone- receptor (PR) negative and HER2 (human epidermal growth factor receptor–2) positive. She received neoadjuvant chemotherapy with adriamycin plus docetaxel for 6 cycles, followed by right mastectomy and prophylactic left mastectomy. There was no residual disease in the breast. After mastectomy, the patient underwent CMF (cyclophosphamide, methotrexate, and fluorouracil) chemotherapy for 3 months, as well as radiation therapy to the chest wall. Adjuvant trastuzumab was started concurrently with the CMF chemotherapy, and was continued for 1 year.
*For a PDF of the full article, click on the link to the left of this introduction.